MEGA Trial: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
Rim Halaby (talk | contribs) No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
'''Click [[media:MEGA_Trial.ppt|here]] to download slides for MEGA Trial.''' | |||
==Objective== | ==Objective== | ||
To assess whether evidence for treatment of [[hypercholesterolemia]] with [[statin]]s derived from western populations can be extrapolated to the Japanese population. | To assess whether evidence for treatment of [[hypercholesterolemia]] with [[statin]]s derived from western populations can be extrapolated to the Japanese population. | ||
Revision as of 16:10, 19 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
MEGA Trial On the Web |
|
American Roentgen Ray Society Images of MEGA Trial |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Click here to download slides for MEGA Trial.
Objective
To assess whether evidence for treatment of hypercholesterolemia with statins derived from western populations can be extrapolated to the Japanese population.
Methods
Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study) was a prospective, randomized, open-labelled, blinded study which enrolled 8214 Japanese men and postmenopausal women aged 40 to 70 years and with a serum total cholesterol concentration of 220 to 270 mg/dL. All the patients were randomly assigned to receive either diet therapy alone or diet therapy plus pravastatin 10 to 20 mg daily and followed-up for a mean period of 5.3 years.
Results
The following results were obtained at the end of follow-up period:
- Mean total cholesterol was reduced by 2.1% and 11.5% in the patients treated with diet alone and diet plus pravastatin respectively.
- Similarly mean LDL-C reduced by 3.2% and 18.0%.
- Significantly lower CAD in patients treated with diet plus pravastatin than in those treated with diet alone.
Conclusion
Treatment with a low dose of pravastatin reduces the risk of CAD in Japan by much the same amount as higher doses have shown in Europe and the USA.[1][2]
References
- ↑ Nakamura H, Arakawa K, Itakura H; et al. (2006). "Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial". Lancet. 368 (9542): 1155–63. doi:10.1016/S0140-6736(06)69472-5. PMID 17011942. Unknown parameter
|month=ignored (help) - ↑ Nakamura H (2009). "[Primary prevention trial by lowering hyperlipidemia on the cardiovascular disease (MEGA Study)]". Nihon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics (in Japanese). 46 (1): 18–21. PMID 19246826. Unknown parameter
|month=ignored (help)